title: Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.
abstract: Bladder cancer is the fourth most common type of cancer in men (ninth in women) in the United States. Cisplatin is an effective agent against the most common subtype, urothelial carcinoma. However, the development of chemotherapy resistance is a severe clinical problem for the successful treatment of this and other cancers. A better understanding of the cellular and molecular events in response to cisplatin treatment and the development of resistance are critical to improve the therapeutic options for patients. Here, we report that expression of the CCAAT/enhancer binding protein delta (CEBPD, C/EBPdelta, NF-IL6beta) is induced by cisplatin in the human bladder urothelial carcinoma NTUB1 cell line and is specifically elevated in a cisplatin resistant subline. Expression of CEBPD reduced cisplatin-induced reactive oxygen species (ROS) and apoptosis in NTUB1 cells by inducing the expression of Cu/Zn-superoxide dismutase (SOD1) via direct promoter transactivation. Several reports have implicated CEBPD as a tumor suppressor gene. This study reveals a novel role for CEBPD in conferring drug resistance, suggesting that it can also be pro-oncogenic. Furthermore, our data suggest that SOD inhibitors, which are already used as anti-angiogenic agents, may be suitable for combinatorial chemotherapy to prevent or treat cisplatin resistance in bladder and possibly other cancers.
authors.affiliation: Department of Medicine, Graduate Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Tzyh-Chyuan
authors.initials: TC
authors.lastname: Hour
authors.forename: Yan-Liang
authors.initials: YL
authors.lastname: Lai
authors.forename: Ching-I
authors.initials: CI
authors.lastname: Kuan
authors.forename: Chen-Kung
authors.initials: CK
authors.lastname: Chou
authors.forename: Ju-Ming
authors.initials: JM
authors.lastname: Wang
authors.forename: Huang-Yao
authors.initials: HY
authors.lastname: Tu
authors.forename: Huei-Ting
authors.initials: HT
authors.lastname: Hu
authors.forename: Chang-Shen
authors.initials: CS
authors.lastname: Lin
authors.forename: Wen-Jeng
authors.initials: WJ
authors.lastname: Wu
authors.forename: Yeong-Shiau
authors.initials: YS
authors.lastname: Pu
authors.forename: Esta
authors.initials: E
authors.lastname: Sterneck
authors.forename: A-Mei
authors.initials: AM
authors.lastname: Huang
mesh_terms: D017209:Apoptosis / Q000235:genetics; D051743:CCAAT-Enhancer-Binding Protein-delta / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D013482:Superoxide Dismutase / Q000096:biosynthesis* / Q000235:genetics; D000072105:Superoxide Dismutase-1; D014158:Transcription, Genetic / Q000187:drug effects / Q000502:physiology; D015533:Transcriptional Activation / Q000187:drug effects / Q000502:physiology*; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*
chemical_list: C497252:CEBPD protein, human; C000606290:SOD1 protein, human; D051743:CCAAT-Enhancer-Binding Protein-delta; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D002945:Cisplatin
references.citation: Development. 2005 Nov;132(21):4675-85
references.pmid: 16192306
references.citation: Anticancer Res. 2000 Sep-Oct;20(5A):3221-5
references.pmid: 11062746
references.citation: Curr Med Chem. 2007;14(14):1499-503
references.pmid: 17584059
references.citation: Dev Cell. 2002 Mar;2(3):331-41
references.pmid: 11879638
references.citation: PLoS One. 2007 Dec 19;2(12):e1334
references.pmid: 18092000
references.citation: J Biol Chem. 2003 Apr 25;278(17):15178-84
references.pmid: 12578822
references.citation: J Biol Chem. 1998 Oct 30;273(44):28545-8
references.pmid: 9786841
references.citation: Biochim Biophys Acta. 2008 Oct;1783(10):1803-14
references.pmid: 18619497
references.citation: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references.pmid: 15789122
references.citation: Curr Opin Oncol. 2009 May;21(3):272-7
references.pmid: 19370808
references.citation: Gene. 1999 Jun 24;234(1):87-91
references.pmid: 10393242
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v106-12
references.pmid: 16807436
references.citation: Cancer Cell. 2006 Apr;9(4):287-300
references.pmid: 16616334
references.citation: J Theor Biol. 1976 Jul 7;59(2):253-76
references.pmid: 957690
references.citation: Oncogene. 2003 Oct 20;22(47):7265-79
references.pmid: 14576837
references.citation: BJU Int. 2005 May;95(7):1086-90
references.pmid: 15839938
references.citation: Br J Cancer. 1997;76(2):206-10
references.pmid: 9231920
references.citation: J Formos Med Assoc. 1992 Jun;91(6):608-13
references.pmid: 1358347
references.citation: Oncogene. 2005 Feb 24;24(9):1589-97
references.pmid: 15674331
references.citation: J Cell Sci. 2005 Jun 15;118(Pt 12):2545-55
references.pmid: 15944395
references.citation: Cancer Chemother Pharmacol. 2009 Mar;63(4):723-30
references.pmid: 18622615
references.citation: Biochem J. 2002 Aug 1;365(Pt 3):561-75
references.pmid: 12006103
references.citation: Clin Cancer Res. 2009 Oct 1;15(19):5945-6
references.pmid: 19789327
references.citation: Oncogene. 2004 Feb 26;23(8):1549-57
references.pmid: 14716301
references.citation: Prostate. 2005 May 1;63(2):143-54
references.pmid: 15486993
references.citation: Anticancer Drugs. 2002 Mar;13(3):293-300
references.pmid: 11984073
references.citation: Trends Biochem Sci. 1995 Oct;20(10):435-9
references.pmid: 8533159
references.citation: Mol Cancer Res. 2003 Mar;1(5):362-75
references.pmid: 12651909
references.citation: Cell Cycle. 2006 May;5(9):953-7
references.pmid: 16687924
references.citation: Anticancer Drugs. 2004 Sep;15(8):779-85
references.pmid: 15494640
references.citation: Curr Opin Pharmacol. 2007 Aug;7(4):392-7
references.pmid: 17611157
references.citation: Nat Rev Drug Discov. 2009 Jul;8(7):579-91
references.pmid: 19478820
references.citation: Int J Biochem Cell Biol. 2007;39(1):44-84
references.pmid: 16978905
references.citation: Gene. 2004 Aug 4;337:1-13
references.pmid: 15276197
references.citation: Nucleic Acids Res. 1995 Nov 25;23(22):4726-33
references.pmid: 8524667
references.citation: Cancer Lett. 2001 Oct 10;171(2):133-8
references.pmid: 11520596
references.citation: Mol Cancer Ther. 2004 Jul;3(7):823-32
references.pmid: 15252143
references.citation: Biochim Biophys Acta. 2006 Aug;1766(1):88-103
references.pmid: 16616425
references.citation: Exp Toxicol Pathol. 2009 May;61(3):223-42
references.pmid: 18986801
references.citation: Neurobiol Dis. 2006 Jan;21(1):18-28
references.pmid: 16040250
references.citation: Biomed Pharmacother. 2005 May;59(4):139-42
references.pmid: 15862706
references.citation: Crit Rev Oncol Hematol. 2009 Mar;69(3):211-22
references.pmid: 18640849
references.citation: Breast Cancer Res Treat. 2006 Jan;95(2):161-70
references.pmid: 16322893
references.citation: J Biol Chem. 1992 Mar 15;267(8):5021-4
references.pmid: 1371993
references.citation: Int J Mol Med. 2004 Jun;13(6):883-7
references.pmid: 15138630
references.citation: Microvasc Res. 2009 May;77(3):314-26
references.pmid: 19323979
references.citation: Mol Cell Biochem. 2002 Nov;240(1-2):47-55
references.pmid: 12487371
references.citation: Jpn J Clin Oncol. 2004 Mar;34(3):124-30
references.pmid: 15078907
references.citation: J Neurosci. 2004 Aug 18;24(33):7324-34
references.pmid: 15317858
references.citation: Trends Cell Biol. 2007 Jul;17(7):318-24
references.pmid: 17658261
references.citation: Cancer Lett. 2008 Jul 18;266(1):30-6
references.pmid: 18372105
references.citation: Curr Med Chem Anticancer Agents. 2005 Jan;5(1):15-27
references.pmid: 15720258
references.citation: J Biol Chem. 1999 Aug 20;274(34):23887-92
references.pmid: 10446154
references.citation: Cancer Biol Ther. 2008 Dec;7(12):1875-84
references.pmid: 18981733
references.citation: Curr Med Chem Anticancer Agents. 2005 May;5(3):251-65
references.pmid: 15992353
references.citation: Nucleic Acids Res. 1998 Jan 1;26(1):362-7
references.pmid: 9399875
references.citation: Mol Cancer Ther. 2003 Mar;2(3):317-32
references.pmid: 12657727
references.citation: Br J Cancer. 2008 Feb 26;98(4):776-83
references.pmid: 18253124
references.citation: Nucleic Acids Res. 2006 Jan 05;34(1):217-31
references.pmid: 16397300
references.citation: Cancer Biol Ther. 2007 Dec;6(12):1858-66
references.pmid: 18087215
references.citation: Mol Cell Biol. 2005 Dec;25(23):10273-85
references.pmid: 16287844
references.citation: J Biol Chem. 2003 Oct 3;278(40):38966-9
references.pmid: 12871978
references.citation: J Biol Chem. 2006 Sep 15;281(37):26769-73
references.pmid: 16873376
references.citation: J Biol Chem. 2008 Nov 7;283(45):30919-32
references.pmid: 18753137
references.citation: Cancer Treat Rev. 2007 Feb;33(1):9-23
references.pmid: 17084534